Psoriatic Arthritis

Compounds in the body may help reduce inflammation and prevent damage to healthy tissues for arthritis patients and patients with other inflammatory diseases.

Researchers warn that non-steroidal anti-inflammatory drugs (NSAIDs) are more dangerous than previously thought, and should be prescribed with great care among patients with heart disease.

Researchers have concluded that there is a small but significant genetic component to the observed connection between high body mass index (BMI) and psoriasis.

An analysis of health records indicates that smoking is not associated with joint damage in psoriatic arthritis patients.

Researchers explored how people aged 16 to 25 years old with inflammatory arthritis evaluate the risks and benefits of treatment. They especially wanted to focus on the patients’ assessments of biologic therapies.

An analysis of records from the Toronto Psoriatic Arthritis Cohort concluded that baseline characteristics can help predict which patients will and will not develop erosions.

Top-line results from a phase 3 trial indicate that twice-daily tofacitinib 5 mg and 10 mg are both superior to placebo in the treatment of psoriatic arthritis.

Several symptoms, including nail pitting and uveitis, may indicate an increased risk for developing psoriatic arthritis.

The FDA has approved Inflectra (infliximab-dyyb/Celltrion, Inc), the biosimilar for Remicade (infliximab) for the treatment of patients suffering from serious autoimmune diseases.

Analysis of 3 apremilast trials finds that the medication increases workplace productivity and reduces workplace limitations for at least a year in patients who began trials with inadequately controlled psoriatic arthritis.

A new analysis of treatment costs and trial outcomes concludes that immediate use of tumor necrosis factor inhibitors (TNFis) is a cost-effective strategy for managing psoriatic arthritis patients with both skin and joint involvement but not for managing those patients with joint disease alone.

A new trial of magnetic resonance imaging finds that analyzing scans for subclinical signs of inflammatory joint disease can help predict which psoriasis patients will go on to develop psoriatic arthritis.

A 96-week-long trial of etanercept (Enbrel) indicates durable therapeutic benefits and no serious adverse events in pediatric patients with psoriatic arthritis and other types of juvenile idiopathic arthritis.

Patients with arthritis may eventually be able to use their own "microvesicles" as treatment for their disease.

Analysis of questionnaire data has identified 5 factors that help predict which patients with chronic inflammatory rheumatic diseases such as psoriatic arthritis will abandon biologic treatment.

A recent report found there is not nearly enough scientific research being conducted on the effects of marijuana and other cannabinoids on rheumatic diseases.

Neither psoriatic arthritis (PsA) nor cutaneous psoriasis (PsC) are considered risk factors for patients undergoing total hip arthroplasty (THA).

Part of an ongoing series that takes a high-level look at the positions of the leading nominees for President when it comes to political issues potentially impacting physicians, this installment focuses on Bernie Sanders.

Part of an ongoing series that takes a high-level look at the positions of the leading nominees for President when it comes to political issues potentially impacting physicians, this installment focuses on Marco Rubio.

A new study comparing psoriatic arthritis patients who do and do not develop cardiovascular disease suggests a strong connection between arthritis that’s polyarticular at onset and diabetes and subsequent strokes and coronary events.

The FDA has granted approval for betamethasone diproprionate (Sernivo Spray/ Dr. Reddy-Promius Pharma) to treat mild-to-moderate plaque psoriasis in patients at least 18 years of age.

Psoriatic arthritis, a chronic skin condition that affects patients on physically and mentally – often impacts patients’ mobility in their daily lives. Healthcare professionals across all specialties have experience when dealing with these patients in different capacities.

Doing yoga improved rheumatoid arthritis and osteoarthritis and mood for female adults following trend of benefits associated with other conditions.

New analysis of data from longitudinal cohorts finds that psoriatic arthritis patients were more than 50% more likely than those with psoriasis but no arthritis to develop infection. It also provides further evidence that biologic medications are also a risk factor for infection.

Connective tissue disease (CTD) groups together various disorders, such as rheumatoid arthritis and lupus. A new study from the University of Chicago found that complications from these diseases are more prominent based on race.

A recent study revealed the pathogenic similarities and differences between cutaneous psoriasis and psoriatic arthritis.

Developing arthritis could increase the risk of falling into poverty, especially for female patients.

Blood analysis in patients with inflammatory rheumatic diseases such as psoriatic arthritis indicates that biologic medications do not reduce the efficacy of anti-pneumococcal polysaccharide vaccine, and that patients with such conditions may not need to be vaccinated more frequently than others.

Age matters when it comes to patients’ access to psoriasis treatment.

Biologic drug secukinumab (Cosentyx/Novartis), already FDA approved in January 2015 to treat chronic plaque psoriasis, has now been approved for two new indications: the treatment of active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).